Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
about
Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.Complex prolactin crosstalk in breast cancer: new therapeutic implicationsPineal Diffuse Large B-Cell Lymphoma Concomitant With Pituitary Prolactinoma: Possible Correlation Between 2 Distinguished Pathologies: A Case Report.Impaired turnover of prolactin receptor contributes to transformation of human breast cells.Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo
P2860
Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Enhancement of the efficacy of ...... ated metastatic breast cancer.
@ast
Enhancement of the efficacy of ...... ated metastatic breast cancer.
@en
type
label
Enhancement of the efficacy of ...... ated metastatic breast cancer.
@ast
Enhancement of the efficacy of ...... ated metastatic breast cancer.
@en
prefLabel
Enhancement of the efficacy of ...... ated metastatic breast cancer.
@ast
Enhancement of the efficacy of ...... ated metastatic breast cancer.
@en
P2093
P1433
P1476
Enhancement of the efficacy of ...... eated metastatic breast cancer
@en
P2093
A Ardizzoia
L Frontini
M S Perego
P304
P407
P577
2004-11-01T00:00:00Z